Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1045 results
October 2015
-
Media ReleaseLong-term efficacy of Gilenya® reinforced by new 'no evidence of disease activity' (NEDA-4) analysis in MS patients over seven yearsNEDA-4 - no evidence of disease activity based on four parameters - relapses, MRI lesions, brain shrinkage and disability progression - is a comprehensive measure of MS disease control 31.2%…
-
Media ReleaseAlcon receives FDA Approval for pre-loaded intraocular lens delivery system to treat patients undergoing cataract surgeryAcrySof® IQ Aspheric Intraocular Lens (IOL) with UltraSertTM Pre-loaded Delivery System helps maintain integrity of incision while facilitating smooth IOL delivery Follows earlier FDA approval…
-
Media ReleaseFDA accepts Sandoz regulatory submission for a proposed biosimilar etanerceptEtanercept is an anti-TNF medicine used to treat a range of immunological diseases including rheumatoid arthritis and psoriasis. Sandoz is seeking approval for all indications included in the…
September 2015
-
Media ReleaseNovartis announces NEJM publication of secukinumab Phase III data confirming significant efficacy in patients with psoriatic arthritisIn the FUTURE 1 study, secukinumab showed rapid and significant efficacy in active psoriatic arthritis (PsA) patients, including improvement of skin and joint disease and reduction in progression of…
-
Media ReleasePatients with aggressive form of melanoma lived for more than two years on average when taking Novartis therapies Tafinlar® + Mekinist®Phase III data showed median overall survival of 25.6 months in patients with BRAF+ V600E/K metastatic melanoma who received Tafinlar + Mekinist Tafinlar + Mekinist combination also demonstrated…
-
Media ReleaseNovartis drug Afinitor® significantly improves progression-free survival in advanced nonfunctional gastrointestinal and lung NETIn pivotal study, everolimus reduced risk of disease progression by 52%; showed 11.0-month median progression-free survival vs 3.9 months for placebo[1] Advanced, progressive, nonfunctional…
-
Media ReleaseNovartis' new heart failure medicine Entresto(TM) recommended by CHMP for EU approvalPositive opinion from EU review body puts Entresto on track to be approved for HFrEF patients across Europe likely by year end Entresto was studied in world's largest heart failure trial which…
-
Media ReleaseNovartis appoints James E. Bradner, MD as President of the Novartis Institutes for BioMedical Research as Mark Fishman retiresNew leader to continue to drive long-term innovation in Novartis research in wide range of therapeutic areas Basel, September 24, 2015 - Novartis announced today that Dr. James (Jay) E.…
-
Media ReleaseNovartis launches 'Novartis Access', a portfolio of affordable medicines to treat chronic diseases in lower-income countriesFirst-of-its-kind portfolio approach in healthcare industry, aiming to increase availability and affordability of 15 medicines against cardiovascular diseases, diabetes, respiratory illnesses and…
-
Media ReleaseSwissmedic approves Novartis' new heart failure medicine Entresto(TM)Decision by Swiss Health Authority follows US Food and Drug Administration (FDA) approval of Entresto in July, serves as an important reference approval for multiple other health authorities…
-
Media ReleaseNovartis Foundation healthcare models and disease elimination programs showcased at ECTMIHTelemedicine pilot in rural Ghana demonstrated positive impact and improved primary health services as reported by nurses, midwives and patients Retrospective contact tracing of former leprosy…
-
Media ReleaseNovartis receives EU approval for Farydak®, the first in its class of anticancer agents approved for patients with multiple myelomaFarydak (panobinostat) combination is approved in the EU for patients with multiple myeloma who received >=2 prior regimens including bortezomib and IMiD[1] In clinical trials, Farydak…
Pagination
- ‹ Previous page
- 1
- …
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- …
- 88
- › Next page